RU2012105641A - Фолатнацеленные диагностические средства и лечение - Google Patents
Фолатнацеленные диагностические средства и лечение Download PDFInfo
- Publication number
- RU2012105641A RU2012105641A RU2012105641/15A RU2012105641A RU2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641/15 A RU2012105641/15 A RU 2012105641/15A RU 2012105641 A RU2012105641 A RU 2012105641A RU 2012105641 A RU2012105641 A RU 2012105641A
- Authority
- RU
- Russia
- Prior art keywords
- tumor
- patient
- administering
- folate receptors
- clinical benefit
- Prior art date
Links
- 238000000034 method Methods 0.000 claims abstract 72
- 206010028980 Neoplasm Diseases 0.000 claims abstract 40
- 102000006815 folate receptor Human genes 0.000 claims abstract 23
- 108020005243 folate receptor Proteins 0.000 claims abstract 23
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract 15
- 230000002285 radioactive effect Effects 0.000 claims abstract 13
- 201000010099 disease Diseases 0.000 claims abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 8
- 230000004083 survival effect Effects 0.000 claims abstract 7
- 208000020816 lung neoplasm Diseases 0.000 claims abstract 6
- 229940014144 folate Drugs 0.000 claims abstract 5
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract 5
- 235000019152 folic acid Nutrition 0.000 claims abstract 5
- 239000011724 folic acid Substances 0.000 claims abstract 5
- 208000037841 lung tumor Diseases 0.000 claims abstract 5
- 230000005764 inhibitory process Effects 0.000 claims abstract 2
- 230000004614 tumor growth Effects 0.000 claims abstract 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 12
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 11
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 10
- 230000001225 therapeutic effect Effects 0.000 claims 9
- 206010033128 Ovarian cancer Diseases 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 229960004679 doxorubicin Drugs 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 5
- 229910052697 platinum Inorganic materials 0.000 claims 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- -1 monosubstituted sodium phosphate monohydrate Chemical class 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- 238000011002 quantification Methods 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- CRKADHVTAQCXRA-UHFFFAOYSA-K trisodium;phosphate;dihydrate Chemical class O.O.[Na+].[Na+].[Na+].[O-]P([O-])([O-])=O CRKADHVTAQCXRA-UHFFFAOYSA-K 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 239000008215 water for injection Substances 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 208000023965 endometrium neoplasm Diseases 0.000 claims 1
- 230000003871 intestinal function Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 201000006385 lung benign neoplasm Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 239000006201 parenteral dosage form Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23059509P | 2009-07-31 | 2009-07-31 | |
| US61/230,595 | 2009-07-31 | ||
| US34644410P | 2010-05-19 | 2010-05-19 | |
| US61/346,444 | 2010-05-19 | ||
| US35102210P | 2010-06-03 | 2010-06-03 | |
| US61/351,022 | 2010-06-03 | ||
| PCT/US2010/043992 WO2011014821A1 (en) | 2009-07-31 | 2010-07-30 | Folate-targeted diagnostics and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012105641A true RU2012105641A (ru) | 2013-09-10 |
Family
ID=43529728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012105641/15A RU2012105641A (ru) | 2009-07-31 | 2010-07-30 | Фолатнацеленные диагностические средства и лечение |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20120128587A1 (enExample) |
| EP (1) | EP2460013A4 (enExample) |
| JP (1) | JP2013501224A (enExample) |
| KR (1) | KR20120050462A (enExample) |
| CN (2) | CN102549434A (enExample) |
| AU (1) | AU2010278734A1 (enExample) |
| BR (1) | BR112012002064A2 (enExample) |
| CA (1) | CA2769754A1 (enExample) |
| IL (1) | IL217744A0 (enExample) |
| IN (1) | IN2012DN01708A (enExample) |
| NZ (1) | NZ598145A (enExample) |
| RU (1) | RU2012105641A (enExample) |
| WO (1) | WO2011014821A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3838298B1 (en) | 2007-08-17 | 2025-02-26 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| MX2013005196A (es) | 2010-11-12 | 2013-06-28 | Endocyte Inc | Metodos para tratamiento del cancer. |
| CN103607891A (zh) * | 2011-04-12 | 2014-02-26 | 恩多塞特公司 | 固体药用组合物 |
| EA201890915A1 (ru) | 2012-11-15 | 2018-09-28 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
| US20140154702A1 (en) * | 2012-11-30 | 2014-06-05 | Endocyte, Inc. | Methods For Treating Cancer Using Combination Therapies |
| US10188738B2 (en) | 2013-10-16 | 2019-01-29 | Université Libre de Bruxelles | Formulations useful in the treatment of proliferative diseases affecting the respiratory tract |
| HRP20240398T1 (hr) | 2013-10-18 | 2024-06-07 | Novartis Ag | Označeni inhibitori prostata specifičnog membranskog antigena (psma), njihova upotreba kao sredstava za snimanje i farmaceutska sredstva za liječenje raka prostate |
| KR102457827B1 (ko) | 2013-11-14 | 2022-10-24 | 엔도사이트, 인코포레이티드 | 양전자 방출 단층 촬영용 화합물 |
| ES2745799T3 (es) | 2013-11-19 | 2020-03-03 | Purdue Research Foundation | Método de selección de pacientes para inflamación |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| CN107427009A (zh) * | 2015-01-11 | 2017-12-01 | 恩多塞特公司 | 癌症成像剂 |
| IL237525A (en) | 2015-03-03 | 2017-05-29 | Shalom Eli | Method for labeling a prostate-specific membrane antigen with a radioactive isotope |
| CN110678204A (zh) * | 2016-03-29 | 2020-01-10 | 恩多塞特公司 | 用于靶向肿瘤相关巨噬细胞的叶酸缀合物 |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| AU2017271550B2 (en) * | 2016-05-25 | 2023-11-02 | Endocyte, Inc. | Method of treating cancer by targeting myeloid-derived suppressor cells |
| CN112368024A (zh) | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1592457T3 (da) * | 2003-01-27 | 2012-10-22 | Endocyte Inc | Folat-vinblastin-konjugat som lægemiddel |
| AU2005318984B2 (en) * | 2004-12-21 | 2011-12-01 | Nektar Therapeutics | Stabilized polymeric thiol reagents |
| EP2452695A3 (en) * | 2004-12-23 | 2013-01-23 | Purdue Research Foundation | Positron emission tomography imaging method |
| EP1863816B1 (en) * | 2005-03-16 | 2014-06-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
| EP1864133B1 (en) * | 2005-03-30 | 2010-03-10 | Purdue Research Foundation | Method for breastcancer prognosis using cellular folate vitamin receptor quantification |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2010507659A (ja) * | 2006-10-25 | 2010-03-11 | シェーリング コーポレイション | 卵巣癌を処置する方法 |
| CN104383553A (zh) * | 2007-06-25 | 2015-03-04 | 恩多塞特公司 | 含有亲水性间隔区接头的共轭物 |
-
2010
- 2010-07-30 IN IN1708DEN2012 patent/IN2012DN01708A/en unknown
- 2010-07-30 CN CN2010800434602A patent/CN102549434A/zh active Pending
- 2010-07-30 NZ NZ598145A patent/NZ598145A/en not_active IP Right Cessation
- 2010-07-30 AU AU2010278734A patent/AU2010278734A1/en not_active Abandoned
- 2010-07-30 CA CA2769754A patent/CA2769754A1/en not_active Abandoned
- 2010-07-30 WO PCT/US2010/043992 patent/WO2011014821A1/en not_active Ceased
- 2010-07-30 EP EP10805137A patent/EP2460013A4/en not_active Withdrawn
- 2010-07-30 JP JP2012523104A patent/JP2013501224A/ja active Pending
- 2010-07-30 BR BR112012002064A patent/BR112012002064A2/pt not_active IP Right Cessation
- 2010-07-30 CN CN201510160314.2A patent/CN104857534A/zh active Pending
- 2010-07-30 US US13/388,184 patent/US20120128587A1/en not_active Abandoned
- 2010-07-30 RU RU2012105641/15A patent/RU2012105641A/ru not_active Application Discontinuation
- 2010-07-30 KR KR1020127005358A patent/KR20120050462A/ko not_active Ceased
-
2012
- 2012-01-26 IL IL217744A patent/IL217744A0/en unknown
-
2013
- 2013-03-13 US US13/800,309 patent/US20140140925A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120050462A (ko) | 2012-05-18 |
| NZ598145A (en) | 2014-10-31 |
| CA2769754A1 (en) | 2011-02-03 |
| AU2010278734A1 (en) | 2012-02-23 |
| JP2013501224A (ja) | 2013-01-10 |
| US20140140925A1 (en) | 2014-05-22 |
| IN2012DN01708A (enExample) | 2015-06-05 |
| WO2011014821A1 (en) | 2011-02-03 |
| US20120128587A1 (en) | 2012-05-24 |
| EP2460013A1 (en) | 2012-06-06 |
| CN104857534A (zh) | 2015-08-26 |
| EP2460013A4 (en) | 2013-04-03 |
| BR112012002064A2 (pt) | 2017-05-09 |
| IL217744A0 (en) | 2012-03-29 |
| CN102549434A (zh) | 2012-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012105641A (ru) | Фолатнацеленные диагностические средства и лечение | |
| Wang et al. | HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib | |
| Wick et al. | Current status and future directions of anti-angiogenic therapy for gliomas | |
| Mégalizzi et al. | 4-IBP, a σ1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs | |
| Infante et al. | Phase I dose-escalation studies of SNX-5422, an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumours | |
| Spiegelberg et al. | The MDM2/MDMX-p53 antagonist PM2 radiosensitizes wild-type p53 tumors | |
| US20250325553A1 (en) | Methods of treating cancer | |
| JP2013501224A5 (enExample) | ||
| JP7113619B2 (ja) | リポソーマルイリノテカンによる乳がんの治療 | |
| Isambert et al. | Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer—results of a first-in-man dose-escalation study with a fixed-dose extension phase | |
| Wagner et al. | Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour | |
| KR20180082428A (ko) | 성장 호르몬 결핍의 검출 및 치료 | |
| Kaartinen et al. | Haemodynamic interactions of medetomidine and the peripheral alpha-2 antagonist MK-467 during step infusions in isoflurane-anaesthetised dogs | |
| Lin et al. | Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer | |
| Maino et al. | Refill procedures of intrathecal drug delivery systems with a recessed fill port on the pump surface: A prospective comparison study of ultrasound-guided vs. blind refill technique | |
| JP2018538370A (ja) | デシタビン、５アザシチジンおよびテトラヒドロウリジンを含有する組成物およびその使用 | |
| Su et al. | Treatment of chemotherapy-induced neutropenia in a rat model by using multiple daily doses of oral administration of G-CSF-containing nanoparticles | |
| Huang et al. | Toxic myelitis and arachnoiditis after intrathecal delivery of bupivacaine via an implanted drug delivery system: case report and review of the literature | |
| CN110638802A (zh) | Atca在制备治疗肿瘤的药物中的用途 | |
| ES3024982T3 (en) | Injection containing p-boronophenylalanine | |
| Apfelbaum et al. | LGG-02. ELUCIDATING THE ROLE OF FGFR1 ALTERATIONS IN PEDIATRIC GLIOMAS | |
| Mohan et al. | 67P Efficacy and safety of trastuzumab biosimilar in HER2+ ve metastatic breast cancer: A multicenter phase III study | |
| Goldstein et al. | 4 HMGB1 DETECTION IN PATIENTS WITH CEREBRAL AND MYOCARDIAL ISCHEMIA | |
| WO2011139867A2 (en) | Method of treating brain cancer | |
| Hernowo et al. | Intravenous hydrogen nanobubbles effect on cardiac physiology and quality of life: a single blind, dose-response study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160126 |